South Korea's Hanmi Pharmaceutical Co. plans to develop the GLP-1 class "Epeglenatide," which it received as a technology return from Sanofi S.A., into a personalized obesity drug for domestic. This decision is based on the assessment that there is a market potential for developing a therapeut
Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean pharmaceutical company Hanmi Pharmaceutical Co., was granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatme
South Korea's Hanmi Pharmaceutical Co. last year saw record-high performance thanks to its self-developed drugs, surpassing its previous best year of 2015, when half of sales came from technology export fees for new drug candidates.Considered a prestigious brand of incrementally modified drugs
Rolontis, a neutropenia agent developed by Hanmi Pharmaceutical The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authorization of the white blood cell disease treatment.The FDA will complete its review of